Table 1 Patients’ Characteristics and Association with Tumor Response
Characteristics | Total (N = 118) | Tumor Response | P value | ||
|---|---|---|---|---|---|
CR/PR (N = 15) | SD (N = 41) | PD/NA (N = 62) | |||
Age, median (IQR) | 61.0 (14.0) | 61.0 (45.0) | 60 (15.0) | 61.5 (13.0) | .890 |
≦65 | 74 (62.7) | 9 (60.0) | 26 (63.4) | 39 (62.9) | .972 |
> 65 | 44 (37.3) | 6 (40.0) | 15 (36.6) | 23 (37.1) | |
Gender | .637 | ||||
Male | 58 (49.2) | 7 (46.7) | 18 (43.9) | 33 (53.2) | |
Female | 60 (50.8) | 8 (53.3) | 23 (56.1) | 29 (46.8) | |
ICD-10 cancer site | .390 | ||||
C22.1 - ICCA | 86 (72.9) | 10 (66.7) | 33 (80.4) | 43 (69.4) | |
C23/C24.9 -GB/others | 18 (15.3) | 2 (13.3) | 4 (9.8) | 12 (19.4) | |
C24.0 – ECCA | 9 (7.6) | 3 (20.0) | 2 (4.9) | 4 (6.5) | |
C24.1 – Ampullary | 5 (4.2) | 0 | 2 (4.9) | 3 (4.7) | |
Performance status | .254 | ||||
0/1 | 102 (86.4) | 15 (100.0) | 35 (85.4) | 52 (83.9) | |
2/3 | 16 (13.6) | 0 | 6 (14.6) | 10 (16.1) | |
NLR | 3.9 (3.4) | 3.4 (4.6) | 3.3 (3.1) | 4.4 (3.2) | .202 |
≦7.45 | 100 (84.7) | 14 (93.3) | 35 (85.4) | 51 (82.3) | .559 |
> 7.45 | 18 (15.3) | 1 (6.7) | 6 (14.6) | 11 (17.7) | |
MLR | 0.40 (0.32) | 0.26 (0.28) | 0.29 (0.32) | 0.43 (0.31) | .043 |
≦0.28 | 40 (33.9) | 8 (53.3) | 19 (46.3) | 13 (21.0) | .007 |
> 0.28 | 78 (66.1) | 7 (46.7) | 22 (53.7) | 49 (79.0) | |
PLR | 151.9 (121.2) | 173.8 (115.5) | 132.7 (114.4) | 161.7 (121.7) | .364 |
≦136.4 | 47 (39.8) | 6 (40.0) | 22 (53.7) | 19 (30.6) | .065 |
> 136.4 | 71 (60.2) | 9 (60.0) | 19 (46.3) | 43 (69.4) | |
Albumin (g/dL) | 3.8 (0.9) | 4.0 (1.1) | 3.8 (0.8) | 3.7 (0.8) | .252 |
≦3.5 | 33 (31.4) | 5 (33.3) | 8 (22.9) | 20 (36.4) | .399 |
> 3.5 | 72 (68.6) | 10 (66.7) | 27 (77.1) | 35 (63.6) | |
ALT (U/L) | 30.0 (34.0) | 30.0 (31.0) | 36.0 (56.0) | 27.0 (24.0) | .321 |
≦36 | 68 (58.1) | 9 (60.0) | 21 (51.2) | 38 (62.3) | .532 |
> 36 | 49 (41.9) | 6 (40.0) | 20 (48.8) | 23 (37.7) | |
Bilirubin (mg/dL) | 0.7 (0.8) | 0.4 (0.9) | 0.6 (0.9) | 0.7 (0.9) | .221 |
≦1.3 | 89 (76.1) | 12 (80.0) | 31 (75.6) | 46 (75.4) | .929 |
> 1.3 | 28 (23.9) | 3 (20.0) | 10 (24.4) | 15 (24.6) | |
ALP (U/L) | 159.5 (168.0) | 106.0 (124.5) | 159.0 (207.0) | 173.0 (147.0) | .108 |
≦94 | 30 (26.8) | 7 (50.0) | 11 (29.7) | 12 (19.7) | .061 |
> 94 | 82 (73.2) | 7 (50.0) | 26 (70.3) | 49 (80.3) | |
Creatinine (mg/dL) | 0.7 (0.4) | 0.7 (0.4) | 0.6 (0.3) | 0.7 (0.4) | .814 |
≦1.27 | 115 (97.5) | 15 (100.0) | 39 (95.1) | 61 (98.4) | .470 |
> 1.27 | 3 (2.5) | 0 | 2 (4.9) | 1 (1.6) | |
CA19–9 (U/mL) | 282.4 (2808.4) | 221.9 (3604.4) | 389.9 (1952.9) | 260.7 (3096.2) | .621 |
≦37 | 35 (29.9) | 5 (33.3) | 7 (17.1) | 23 (37.7) | .079 |
> 37 | 82 (70.1) | 10 (66.7) | 34 (82.9) | 38 (62.3) | |
CEA (ng/mL) | 4.3 (15.3) | 4.7 (21.2) | 3.1 (10.3) | 5.6 (19.5) | .259 |
≦5 | 64 (54.2) | 8 (53.3) | 26 (63.4) | 30 (48.4) | .324 |
> 5 | 54 (45.8) | 7 (46.7) | 15 (36.6) | 32 (51.6) | |
Biliary drainage | .398 | ||||
None | 88 (74.6) | 9 (60.0) | 31 (75.7) | 48 (77.5) | |
Internal stenting | 8 (6.8) | 3 (20.0) | 3 (7.3) | 2 (3.2) | |
PTCD | 19 (16.1) | 3 (20.0) | 6 (14.6) | 10 (16.1) | |
Both | 3 (2.5) | 0 | 1 (2.4) | 2 (3.2) | |
Tumor involvement | |||||
Primary tumor | .116 | ||||
No | 8 (6.8) | 0 | 1 (2.4) | 7 (11.3) | |
Yes | 110 (93.2) | 15 (100.0) | 40 (97.6) | 55 (88.7) | |
Regional LAP | .585 | ||||
No | 42 (35.6) | 7 (46.7) | 13 (31.7) | 22 (35.5) | |
Yes | 76 (64.4) | 8 (53.3) | 28 (68.3) | 40 (64.5) | |
Lung | .069 | ||||
No | 95 (80.5) | 15 (100.0) | 34 (82.9) | 46 (74.2) | |
Yes | 23 (19.5) | 0 | 7 (17.1) | 16 (25.8) | |
Bone | .748 | ||||
No | 105 (89.0) | 14 (93.3) | 37 (90.2) | 54 (87.1) | |
Yes | 13 (11.0) | 1 (6.7) | 4 (9.8) | 8 (12.9) | |
Liver | .465 | ||||
No | 69 (58.5) | 10 (66.7) | 26 (63.4) | 33 (53.2) | |
Yes | 49 (41.5) | 5 (33.3) | 15 (36.6) | 29 (46.8) | |
Peritoneum | .436 | ||||
No | 96 (81.4) | 14 (93.3) | 33 (80.5) | 49 (79.0) | |
Yes | 22 (18.6) | 1 (6.7) | 8 (19.5) | 13 (21.0) | |
Distant LAP | .969 | ||||
No | 102 (86.4) | 13 (86.7) | 35 (85.4) | 54 (87.1) | |
Yes | 16 (13.6) | 2 (13.3) | 6 (14.6) | 8 (12.9) | |